Malignant Epithelial Neoplasms

Oncology
3
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Providence Therapeutics
2 programs
2
TCR-transduced T cellsPhase 11 trial
TCR-transduced T cellsPhase 1
Active Trials
NCT04520711Active Not RecruitingEst. Feb 2027
Celldex Therapeutics
1 program
1
TCR-transduced T cellsPhase 11 trial
Active Trials
NCT05349890Active Not Recruiting1Est. Apr 2028

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
Celldex TherapeuticsTCR-transduced T cells
Providence TherapeuticsTCR-transduced T cells

Clinical Trials (2)

Total enrollment: 1 patients across 2 trials

NCT05349890Celldex TherapeuticsTCR-transduced T cells

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Start: Apr 2023Est. completion: Apr 20281 patients
Phase 1Active Not Recruiting

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Start: Feb 2022Est. completion: Feb 2027
Phase 1Active Not Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space